InvestorsObserver
×
News Home

Is Intellia Therapeutics Inc (NTLA) a Stock to Watch After Losing -2.85% This Week?

Tuesday, December 07, 2021 09:52 AM | InvestorsObserver Analysts

Mentioned in this article

Is Intellia Therapeutics Inc (NTLA) a Stock to Watch After Losing -2.85% This Week?

Intellia Therapeutics Inc (NTLA) stock has fallen 2.85% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Intellia Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NTLA!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With NTLA Stock Today?

Intellia Therapeutics Inc (NTLA) stock is trading at $111.73 as of 9:46 AM on Tuesday, Dec 7, a rise of $10.97, or 10.89% from the previous closing price of $100.76. The stock has traded between $105.59 and $112.97 so far today. Volume today is below average. So far 21,561 shares have traded compared to average volume of 690,359 shares. To see InvestorsObserver's Sentiment Score for Intellia Therapeutics Inc click here.

More About Intellia Therapeutics Inc

Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia. Click Here to get the full Stock Report for Intellia Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App